AstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- Update
February 21 2022 - 4:38AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC and Daiichi Sankyo Co. on Monday reported
positive Phase 3 trial results for the Enhertu treatment on breast
cancer patients.
The pharmaceutical companies said Enhertu demonstrated
meaningful survival improvement in patients with breast cancer
compared with physician's choice of chemotherapy.
"Today's historic news from Destiny-Breast04 could reshape how
breast cancer is classified and treated. A HER2-directed therapy
has never-before shown a benefit in patients with HER2-low
metastatic breast cancer," Susan Galbraith, AstraZeneca's executive
vice president for Oncology R&D, said.
The HER2 protein is expressed on the surface of many types of
tumors, and is one of many biomarkers expressed in breast cancer
tumors.
"These results for Enhertu are a huge step forward and could
potentially expand our ability to target the full spectrum of HER2
expression, validating the need to change the way we categorize and
treat breast cancer," she said.
"We look forward to sharing the detailed findings of
Destiny-Breast04 with the medical community and initiating
discussions with regulatory agencies globally with the goal of
potentially bringing Enhertu to patients with metastatic breast
cancer previously considered to be HER2 negative," Ken Takeshita,
global head of R&D at Daiichi Sankyo, said.
The Destiny-Breast04 trial enrolled around 540 patients in Asia,
Europe and North America. AstraZeneca and Daiichi Sankyo have a
50/50 development and commercialization agreement for Enhertu.
Shares in AstraZeneca at 0856 GMT were up 1.5% at 8,934
pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
February 21, 2022 04:23 ET (09:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Aug 2023 to Aug 2024